Axonics to Present at the J.P. Morgan Healthcare Conference
Get Alerts AXNX Hot Sheet
Join SI Premium – FREE
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024.
Interested parties may access a live webcast and replay of the presentation by visiting the Axonics investor relations website.
About Axonics
Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times list of the fastest growing companies in the Americas after being ranked No. 1 in 2022.
Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231227494865/en/
Neil Bhalodkar
949-336-5293
[email protected]
Source: Axonics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GMO Internet Group to Field a Group-Wide Team at “DEF CON 34” CTF, the World’s Premier Cybersecurity Competition
- Pep Boys Marks 105 Years of Keeping America Moving with Founder's Day Celebration
- Comp AI Opens Miami Headquarters and First Dedicated Office in Aventura
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share